ClinicalTrials.gg
RecruitingNCT03142152Updated Apr 13, 2026

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

An interventional study of Carillon Mitral Contour System and Guideline Directed Heart Failure Medication in Functional Mitral Regurgitation, Heart Failure and Mitral Valve Insufficiency, sponsored by Cardiac Dimensions, Inc.. Recruiting at 92 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Cardiac Dimensions, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2018; still recruiting 8 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
367th of 1,602
300 · median 66
Started
2018
with 112 others
No phase
887 of 2,159
159 open now
Primary completion
2026-12
later than 124 of 438 live
Registered
1,153rd of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 367th largest by planned enrollment of the 1,602 interventional ones that give a count, is one of 113 that started in 2018, is one of 887 with no phase, reaches primary completion later than 124 of the 438 other live ones, and was the 1,153rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).

Read the detailed description

A total of 300 subjects will be randomized at up to 100 investigational sites in the United States, Canada, and Europe. Subjects will be randomized into one of two study groups using a 1:1 (Intervention : Control) ratio.

Study subjects who are eligible for this clinical study will undergo a transthoracic echocardiographic examination prior to randomization to evaluate the inclusion criteria associated with the severity of mitral regurgitation. A coronary angiogram will be performed to evaluate the coronary artery anatomy and a venogram to assess the suitability of the coronary sinus/great cardiac vein (CS/GCV) for placement of the Carillon implant.

If the subject meets the anatomic requirements for the Carillon implant placement, the subject will be randomized. Subjects who meet all eligibility criteria will be randomized into one of two study groups (Intervention or Control).

Subjects randomized to the Intervention group will undergo the Carillon implant procedure.

Subjects randomized to the Control group will experience an index procedure similar to the Intervention group (without implant placement) to ensure they will not be able to deduce the group assignment based on the type of intervention or time associated with the procedure.

After the study subjects are discharged, the subjects' primary care specialists (cardiologist/heart failure physician) and clinical investigation site staff will coordinate follow-up evaluations. Subjects will be evaluated at one (1), six (6), twelve (12), eighteen (18) and twenty-four (24) months post-randomization, to assess long-term safety, and functional and clinical status.

After the 24-month evaluation, all subjects will be unblinded. All Intervention and Control subjects will be followed with an abbreviated annual contact and echocardiogram for an additional three (3) years, for a total of five (5) years.

03

Conditions studied

  • Functional Mitral Regurgitation
  • Heart Failure
  • Mitral Valve Insufficiency
  • Heart Diseases
  • Cardiovascular Diseases
  • Heart Valve Diseases

Keywords

  • Functional Mitral Regurgitation
  • Percutaneous Mitral Valve Repair
  • Percutaneous Mitral Valve Annuloplasty
  • Coronary Sinus Annuloplasty
  • Secondary Mitral Regurgitation
  • Functional MR
  • FMR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Symptomatic heart failure with functional (secondary) mitral regurgitation of at least 1+ (mild) severity
  2. II, III, or IV
  3. Six Minute Walk distance ≥ 100 meters and ≤ 600 meters
  4. ≤ 50%
  5. LVEDD:

    • ≥ 55 mm (women)
    • ≥ 57 mm (men)
  6. LVESD ≤ 75 mm
  7. Corrected NT-proBNP > 1200 pg/ml measured within 60 days of randomization, and/or one or more heart failure hospitalizations within one year prior to consent or one or more outpatient visits for intensification of heart failure therapy within one year prior to consent.
  8. Optimal Guideline directed heart failure medical therapy assessed by the Central Review Committee
  9. Age ≥ 18 years old
  10. Carillon implant can be sized and placed in accordance with the IFU
  11. The subject has been informed of the nature of the trial and agrees to its provisions, including the possibility of randomization to the Control group and returning for all required post-procedure follow-up visits, and has provided written

Exclusion criteria

Exclusion Criteria:

  1. Presence of a mechanical or bio-prosthetic mitral valve or, mitral valve annuloplasty, or leaflet repair device
  2. Significant organic mitral valve pathology (e.g., moderate or severe myxomatous degeneration, with or without mitral leaflet prolapse, rheumatic disease, full or partial chordal rupture)
  3. Severe tricuspid regurgitation associated with right ventricular dysfunction and enlargement
  4. Severe mitral annular calcification
  5. Severe aortic stenosis
  6. Expected to require any cardiac surgery, including surgery for coronary artery disease (CAD) or valve disease within one (1) year
  7. Chronic, severe, medical conditions or pathology, other than heart failure, that will prevent likely survival beyond twelve (12) months or any other medical condition that, in the judgement of the Investigator or Central Review Committee, makes the patient a poor candidate for this study

    • An entire list of eligibility is available in the clinical plan
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Carillon Mitral Contour System and Guideline Directed Heart Failure Medication

    Device: Carillon Mitral Contour System · Other: Guideline Directed Heart Failure Medication

  • Active comparator
    Control Group

    Guideline Directed Heart Failure Medication

    Other: Guideline Directed Heart Failure Medication

Interventions

  • DeviceCarillon Mitral Contour System

    The Carillon implant is designed to be deployed, tensioned, and locked in the coronary vein in order to reshape the mitral annulus and thus reduce mitral annular dilation and mitral regurgitation.

    Also known as: Carillon, Percutaneous mitral valve repair

  • OtherGuideline Directed Heart Failure Medication

    Heart failure medication per ACC/AHA guidelines

06

What researchers measure

Primary outcomes

  1. Primary Safety Objective - Freedom from Major Adverse Events

    Freedom from a composite of major adverse events (defined as Device Embolization, Vessel Erosion, Cardiac Perforation, and occurrence of cardiac surgery or percutaneous coronary intervention) in the Intervention group is greater than performance goal of 90%.

    Time frame: 12 months

  2. Primary Efficacy Objective 1 - Hierarchical Clinical Composite

    To demonstrate that the CMCS (Intervention) group is superior to the Control group on the hierarchical composite endpoint of death, Cardiac transplantation or LVAD implantation, unplanned percutaneous or surgical mitral valve intervention, unplanned heart failure hospitalization, change in KCCQ overall summary score, and change in six-minute walk distance at 24 months (analyzed when the last subject completes 12 months of follow-up.)

    Time frame: 24 months

Secondary outcomes

  1. Secondary Efficacy Objective 1- Regurgitant Volume

    To compare regurgitant volume change relative to control from baseline through 12 months of follow up in patients with at least MR grade 2+ at baseline

    Time frame: 12 months

  2. Secondary Efficacy Objective 2 - Change in LV End-diastolic Volume

    To compare the change from baseline left ventricular end-diastolic volume (LVEDV) relative to the Control group.

    Time frame: 12 months

  3. Secondary Efficacy Objective 3 - Change in NYHA

    To compare the change from baseline in New York Heart Association (NYHA) Classification, relative to Control, at twelve (12) months

    Time frame: 12 months

  4. Secondary Efficacy Objective 4 - Hierarchical Clinical Composite

    To compare the first four components of the hierarchical primary efficacy endpoint, relative to Control, analyzed when the last subject completes 12 months of follow up and use all available data up to twenty-four (24) months

    Time frame: 12 months

  5. Secondary Efficacy Objective 5 - Heart Failure Hospitalizations

    To compare total number of HFH, relative to Control, analyzed when the last subject completes 12 months of follow-up and use all available data up to 24 months

    Time frame: 12 months of follow-up, and any available data up to 24 months

  6. Exploratory Secondary Endpoint 1 - Change in Six-Minute Walk Distance

    To compare the change improvement from baseline in six-minute walk distance (6MWD), relative to Control, at twelve (12) months

    Time frame: 12 months

  7. Exploratory Secondary Endpoint 2 - Change in KCCQ

    To compare the change from baseline, relative to the Control group, in the Overall Summary Score (OSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ), at twelve (12) months

    Time frame: 12 months

  8. Exploratory Secondary Endpoint 3 - Change in LV End-systolic Volume

    To compare the change from baseline in left ventricular end-systolic volume (LVESV), relative to Control, at twelve (12) months

    Time frame: 12 months

  9. Exploratory Secondary Endpoint 4 - days lost due to HFH and CV death

    To compare percent days lost due to HFH and CV death relative to Control, analyzed when the last subject completes 12 months of follow-up and use all available data up to 24 months

    Time frame: 12 months of follow-up, and any available data up to 24 months

  10. Exploratory Secondary Endpoint 5 - Alternative Therapies

    To compare the incidence of need for alternative therapy and all-cause mortality (superiority test if HR \< 1), relative to Control, analyzed when the last subject completes 12 months of follow-up and use all available data up to 24 months

    Time frame: 12 months of follow-up, and any available data up to 24 months

07

Study locations

61 of 92 sites recruiting
08

References and documents

Publications

  • Schofer J, Siminiak T, Haude M, Herrman JP, Vainer J, Wu JC, Levy WC, Mauri L, Feldman T, Kwong RY, Kaye DM, Duffy SJ, Tubler T, Degen H, Brandt MC, Van Bibber R, Goldberg S, Reuter DG, Hoppe UC. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation. 2009 Jul 28;120(4):326-33. doi: 10.1161/CIRCULATIONAHA.109.849885. Epub 2009 Jul 13. PubMed 19597051 ↗
  • Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, Fajadet J, Shah AM, Feldman T, Kaye DM, Goldberg SL, Levy WC, Solomon SD, Reuter DG. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail. 2012 Aug;14(8):931-8. doi: 10.1093/eurjhf/hfs076. Epub 2012 May 21. PubMed 22613584 ↗
  • Lipiecki J, Siminiak T, Sievert H, Muller-Ehmsen J, Degen H, Wu JC, Schandrin C, Kalmucki P, Hofmann I, Reuter D, Goldberg SL, Haude M. Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial. Open Heart. 2016 Jul 8;3(2):e000411. doi: 10.1136/openhrt-2016-000411. eCollection 2016. PubMed 27493761 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Dec 2026, 107 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 107 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2017
First posted
May 5, 2017
StartActual
Jan 1, 2018
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2030
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03142152
Lead sponsor
Cardiac Dimensions, Inc.
Responsible party
Sponsor
First posted
May 5, 2017
Start date
Jan 1, 2018
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Apr 13, 2026

Study contacts

Hank Hauser
Contact
hhauser@cardiacdimensions.com
(310) 228-0016
Samir Kapadia, MD
principal investigator · The Cleveland Clinic
Randall Starling, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion